About: Crystal Structure of the Hendra Virus Attachment G Glycoprotein Bound to a Potent Cross-Reactive Neutralizing Human Monoclonal Antibody

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Crystal Structure of the Hendra Virus Attachment G Glycoprotein Bound to a Potent Cross-Reactive Neutralizing Human Monoclonal Antibody Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Crystal Structure of the Hendra Virus Attachment G Glycoprotein Bound to a Potent Cross-Reactive Neutralizing Human Monoclonal Antibody
Creator	Chan, Yee-Peng Zhu, Zhongyu Feldmann, Heinz Xu, Yan Rockx, Barry Xu, Kai Bishop-Lilly, Kimberly Broder, Christopher Debuysscher, Blair Dimitrov, Dimiter Mokashi, Vishwesh Cer, Regina Fusco, Deborah Luu, Truong Nikolov, Dimitar Xie, Yihu
Source	Medline; PMC
abstract	The henipaviruses, represented by Hendra (HeV) and Nipah (NiV) viruses are highly pathogenic zoonotic paramyxoviruses with uniquely broad host tropisms responsible for repeated outbreaks in Australia, Southeast Asia, India and Bangladesh. The high morbidity and mortality rates associated with infection and lack of licensed antiviral therapies make the henipaviruses a potential biological threat to humans and livestock. Henipavirus entry is initiated by the attachment of the G envelope glycoprotein to host cell membrane receptors. Previously, henipavirus-neutralizing human monoclonal antibodies (hmAb) have been isolated using the HeV-G glycoprotein and a human naïve antibody library. One cross-reactive and receptor-blocking hmAb (m102.4) was recently demonstrated to be an effective post-exposure therapy in two animal models of NiV and HeV infection, has been used in several people on a compassionate use basis, and is currently in development for use in humans. Here, we report the crystal structure of the complex of HeV-G with m102.3, an m102.4 derivative, and describe NiV and HeV escape mutants. This structure provides detailed insight into the mechanism of HeV and NiV neutralization by m102.4, and serves as a blueprint for further optimization of m102.4 as a therapeutic agent and for the development of entry inhibitors and vaccines.
has issue date	2013-10-10(xsd:dateTime)
bibo:doi	10.1371/journal.ppat.1003684
bibo:pmid	24130486
has license	cc0
sha1sum (hex)	7dbdecefcd59460800cc11324be0595779ffde80
schema:url	https://doi.org/10.1371/journal.ppat.1003684
resource representing a document's title	Crystal Structure of the Hendra Virus Attachment G Glycoprotein Bound to a Potent Cross-Reactive Neutralizing Human Monoclonal Antibody
has PubMed Central identifier	PMC3795035
has PubMed identifier	24130486
schema:publication	PLoS Pathog
resource representing a document's body	covid:7dbdecefcd59460800cc11324be0595779ffde80#body_text
is schema:about of	named entity 'G GLYCOPROTEIN' named entity 'Bangladesh' named entity 'animal models' named entity 'potential' named entity 'human' named entity 'envelope' named entity 'therapy' named entity 'crystal structure' named entity 'therapies' named entity 'describe' named entity 'Antibody' named entity 'LICENSED' named entity 'OUTBREAKS' named entity 'ATTACHMENT' named entity 'DESCRIBE' named entity 'DERIVATIVE' named entity 'ASSOCIATED WITH' named entity 'COMPASSIONATE USE' named entity 'MUTANTS' named entity 'ESCAPE' named entity 'USE' named entity 'HENDRA VIRUS' named entity 'MONOCLONAL ANTIBODY' named entity 'INFECTION' named entity 'REPEATED' named entity 'THERAPEUTIC AGENT' named entity 'PARAMYXOVIRUSES' named entity 'THERAPIES' named entity 'USING' named entity 'HENIPAVIRUSES' named entity 'CURRENTLY' named entity 'HEV' named entity 'MEMBRANE RECEPTORS' named entity 'DEMONSTRATED' named entity 'BROAD' named entity 'ANTIBODY LIBRARY' named entity 'EXPOSURE THERAPY' named entity 'VIRUS ATTACHMENT' named entity 'HOST' named entity 'ANIMAL MODELS ' named entity 'CRYSTAL STRUCTURE' named entity 'EFFECTIVE' named entity 'CROSS-REACTIVE' named entity 'CRYSTAL STRUCTURE' named entity 'BOUND' named entity 'HUMAN' named entity 'COMPLEX' named entity 'HUMANS' named entity 'BLOCKING' named entity 'MONOCLONAL ANTIBODIES' named entity 'PROVIDES' named entity 'PATHOGENIC' named entity 'TROPISMS' named entity 'HIGHLY' named entity 'NIV' named entity 'HERE' named entity 'INSIGHT' named entity 'MECHANISM' named entity 'ANTIVIRAL' named entity 'PEOPLE' named entity 'ENTRY' named entity 'USED' named entity 'DETAILED' named entity 'AUSTRALIA' named entity 'MORBIDITY AND MORTALITY' named entity 'VACCINES'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software